Small molecule PROTAC® hijacking and structural characterization of an E3 ligase, KLHDC2, for targeted protein degradation
Enhanced Efficacy of ARV-471, a Novel PROTAC® Estrogen Receptor Degrader, in Combination with Targeted Agents in ER+ Breast Cancer Models
Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer
The Arvinas PROTAC® Discovery Engine: PROTAC Biophysical Characterization Fuels The Discovery Of Target And E3 Ligase Ligands For Optimized PROTAC Degrader Molecules